(Q36488198)

14 August 2017

1 reference

title

Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan? (English)

1 reference

14 August 2017

1 reference

1 reference

D Pectasides

1

1 reference

14 August 2017

A Psyrri

series ordinal

2

1 reference

14 August 2017

M Pectasides

series ordinal

3

1 reference

14 August 2017

T Economopoulos

series ordinal

4

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

8

1 reference

14 August 2017

page(s)

975-987

1 reference

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Topotecan in platinum- and paclitaxel-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Clinical pharmacokinetics and dose optimisation of carboplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Workshop: options for therapy in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

The clinical utility of liposomal doxorubicin in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Phase II Study of Pegylated Liposomal Doxorubicin in Heavily Pretreated Epithelial Ovarian Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Oral etoposide is active against platinum-resistant epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

A phase II trial of topotecan in patients with previously untreated pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Phase I and pharmacologic study of topotecan in patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer. Phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Comment on "Comparison of serum vascular endothelial growth levels between patients with and without ovarian malignancies.".

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Single-agent adriamycin followed by combination hexamethylmelamine-cyclophosphamide for advanced ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.8.975

21 January 2018

Identifiers

DOI

10.1517/14656566.7.8.975

1 reference

14 August 2017

1 reference